+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

A new Alzheimer's drug exposes a 'fundamentally flawed' part of how the US pays for drugs

Jun 23, 2021, 19:18 IST
Business Insider
Maree Valenta, who has Alzheimer's disease, undergoes a scan to detect early Alzheimer's in 2004. Photo by Fairfax Media via Getty Images/Fairfax Media via Getty Images via Getty Images

Hi,

Advertisement

Good morning, and welcome back to Insider Healthcare. I'm Andrew Dunn, and today in healthcare news:

If you're new to this newsletter, sign up here. And let me know what we should be paying attention to going forward: adunn@insider.com. On to the news:

Doctors stand to make thousands on a new Alzheimer's drug even if they don't believe it works. It reveals a 'fundamentally flawed' part of America's healthcare system.

Read more on Aduhelm's budget-breaking potential here >>

Pfizer BioNTech COVID-19 vaccine Pete Bannan/MediaNews Group/Daily Local News via Getty Images

Advertisement

US will likely miss Biden's July 4 COVID-19 goal of having 70% of adults vaccinated, White House says

Read more here >>

GlaxoSmithKline CEO Emma Walmsley. Mandel Ngan/Getty Images

With activist investor Elliott breathing down GSK's neck, here are 5 burning questions the pharma giant needs to answer at a critical investor day

Hear more about GSK's big day here >>

More stories we're reading today:

- Andrew

Advertisement
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article